The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis

The Lancet Psychiatry

Volumn 3, Issue 11, 2016, Pages 1049-1058

  Perry, Benjamin Ian ^a,c   McIntosh, Gemma ^d   Weich, Scott ^c   Singh, Swaran ^c,e   Rees, Karen ^b  

^a University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ARTICLE; BLOOD BIOCHEMISTRY; DISEASE ASSESSMENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTATIC MODEL ASSESSMENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PSYCHOSIS; SYSTEMATIC REVIEW; BLOOD; GLUCOSE INTOLERANCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84992145708     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)30262-0     Document Type: Article

References (52)

1. 1 McGrath, J, Saha, S, Chant, D, Welham, J, Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30 (2008), 67–76.
2. 2 Olfson, M, Gerhard, T, Huang, C, Crystal, S, Stroup, TS, Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72 (2015), 1172–1181.
3. 3 Papanastasiou, E, The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 3 (2013), 33–51.
4. 4 Kato, MM, Goodnick, PJ, Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2 (2001), 1571–1582.
5. 5 Kohen, D, Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 47 (2004), S64–S66.
6. 6 Maudsley, H, The pathology of mind. 1895. Facsimile Edition, 1879, Macmillan, London.
7. 7 vanNimwegen, LJ, Storosum, JG, Blumer, RM, et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93 (2008), 572–577.
8. 8 Thakore, JH, Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 47 (2004), S76–S79.
9. 9 Buchsbaum, MS, Buchsbaum, BR, Hazlett, EA, et al. Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am J Psychiatry 164 (2007), 1072–1081.
10. 10 Dandona, P, Aljada, A, Bandyopadhyay, A, Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25 (2004), 4–7.
11. 11 Kubaszek, A, Pihlajamäki, J, Komarovski, V, et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52 (2003), 1872–1876.
12. 12 Calle, MC, Fernandez, ML, Inflammation and type 2 diabetes. Diabetes Metab 38 (2012), 183–191.
13. 13 Pollack, RM, Donath, MY, LeRoith, D, Leibowitz, G, Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39:suppl 2 (2016), S244–S252.
14. 14 Staels, B, Fruchart, JC, Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005), 2460–2470.
15. 15 Esser, N, Paquot, N, Scheen, AJ, Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 24 (2015), 283–307.
16. 16 Hurley, LL, Tizabi, Y, Neuroinflammation, neurodegeneration, and depression. Neurotox Res 23 (2013), 131–144.
17. 17 Sharma, AN, Bauer, IE, Sanches, M, et al. Common biological mechanism between bipolar disorder and type 2 diabetes: focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry 54 (2014), 289–298.
18. 18 Monji, A, Kato, TA, Mizoguchi, Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 42 (2013), 115–121.
19. 19 Drexhage, RC, Knijff, EM, Padmos, RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10 (2010), 59–76.
20. 20 Khandaker, GM, Pearson, RM, Zammit, S, Lewis, G, Jones, PB, Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71 (2014), 1121–1128.
21. 21 Müller, N, Myint, AM, Krause, D, Weidinger, E, Schwarz, MJ, Anti-inflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42 (2013), 146–153.
22. 22 Beumer, W, Drexhage, RC, De Wit, H, Versnel, MA, Drexhage, HA, Cohen, D, Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37 (2012), 1901–1911.
23. 23 Lin, PI, Shuldiner, AR, Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 123 (2010), 234–243.
24. 24 Banks, WA, Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11 (2005), 973–984.
25. 25 Starr, JM, Wardlaw, J, Ferguson, K, MacLullich, A, Deary, IJ, Marshall, I, Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 74 (2003), 70–76.
26. 26 Menezes, NM, Arenovich, T, Zipursky, RB, A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 36 (2006), 1349–1362.
27. 27 Mitchell, AJ, Vancampfort, D, De Herdt, A, Yu, W, De Hert, M, Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull 39 (2013), 295–305.
28. 28 Fernandez-Egea, E, Garcia-Rizo, C, Zimbron, J, Kirkpatrick, B, Diabetes or prediabetes in newly diagnosed patients with nonaffective psychosis? A historical and contemporary view. Schizophr Bull 39 (2013), 266–267.
29. 29 Cohn, TA, Remington, G, Zipursky, RB, Azad, A, Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry, 51, 2006, 382.
30. 30 Haddaway, NR, Collins, AM, Coughlin, D, Kirk, S, The role of Google Scholar in evidence reviews and its applicability to grey literature searching. PLoS One, 10, 2015, e0138237.
31. 31 Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
32. 32 Mellitus, D, Diagnosis and classification of diabetes mellitus. Diabetes Care, 28, 2005, S37.
33. 33 Olson, DE, Rhee, MK, Herrick, K, Ziemer, DC, Twombly, JG, Phillips, LS, Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 33 (2010), 2184–2189.
34. 34 Hermans, MP, Levy, JC, Morris, RJ, Turner, RC, Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42 (1999), 678–687.
35. 35 Wallace, TM, Levy, JC, Matthews, DR, Use and abuse of HOMA modeling. Diabetes Care 27 (2004), 1487–1495.
36. 36 Wells, GA, Shea, B, O'Connell, D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, 2000 (accessed Sept 27, 2016).
37. 37 Petrikis, P, Tigas, S, Tzallas, AT, Papadopoulos, I, Skapinakis, P, Mavreas, V, Parameters of glucose and lipid metabolism at the fasted state in drug-naïve first-episode patients with psychosis: Evidence for insulin resistance. Psychiatry Res 229 (2015), 901–904.
38. 38 Fernandez-Egea, E, Bernardo, M, Donner, T, Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194 (2009), 434–438.
39. 39 Spelman, LM, Walsh, PI, Sharifi, N, Collins, P, Thakore, JH, Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 24 (2007), 481–485.
40. 40 Arranz, B, Rosel, P, Ramírez, N, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65 (2004), 1–478.
41. 41 Ryan, MC, Collins, P, Thakore, JH, Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160 (2003), 284–289.
42. 42 Wu, X, Huang, Z, Wu, R, et al. The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res 150 (2013), 157–162.
43. 43 Kirkpatrick, B, Miller, BJ, Garcia-Rizo, C, Fernandez-Egea, E, Bernardo, M, Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr Bull 38 (2012), 280–284.
44. 44 Dasgupta, A, Singh, OP, Rout, JK, Saha, T, Mandal, S, Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 34 (2010), 1202–1207.
45. 45 Sengupta, S, Parrilla-Escobar, MA, Klink, R, et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr Res 102 (2008), 329–336.
46. 46 Darcin, AE, Cavus, SY, Dilbaz, N, Kaya, H, Dogan, E, Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res 166 (2015), 201–206.
47. 47 Kirkpatrick, B, Fernandez-Egea, E, Garcia-Rizo, C, Bernardo, M, Differences in glucose tolerance between deficit and nondeficitschizophrenia. Schizophr Res 107 (2009), 122–127.
48. 48 Wani, RA, Dar, MA, Margoob, MA, Rather, YH, Haq, I, Shah, MS, Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. J Neurosci Rural Pract, 6, 2015, 17.
49. 49 Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF, Turner, RC, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
50. 50 Rye, KA, Barter, PJ, Cardioprotective functions of HDLs. J Lipid Res 55 (2014), 168–179.
51. 51 Nordestgaard, BG, Chapman, MJ, Humphries, SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 34 (2013), 3478–3490.
52. 52 Brugha, TS, Matthews, R, Morgan, Z, Hill, T, Alonso, J, Jones, DR, Methodology and reporting of systematic reviews and meta-analyses of observational studies in psychiatric epidemiology: systematic review. Br J Psychiatry 200 (2012), 446–453.